FFPE tumor profiling
DNA and DNA+RNA options for solid tumors from tissue biopsy. Covers mutations, fusions, CNVs, MSI, TMB, and HRD where applicable.
Clinical Area · Oncology
Tumor profiling connected to the treatment question
Oncology testing is most useful when the assay, specimen type, and report interpretation are matched to the clinical decision at hand. AC supports physicians from test selection through report review — not just sample forwarding.
Liquid biopsy (cfDNA)
Cell-free DNA profiling from a blood draw. Useful when tissue is unavailable, repeat sampling is needed, or monitoring is required.
Hematologic panels
Molecular profiling for AML, ALL, MDS/MPN, lymphoma, and plasma-cell neoplasms through a curated NGS panel approach.
HRD testing
Homologous recombination deficiency assessment for PARP inhibitor candidacy in ovarian, breast, and other tumor types.
Clinical indications
When to consider molecular oncology testing
Pre-analytic factors — tumor content, FFPE quality, decalcification, RNA integrity, and tissue volume — should be evaluated before selecting an assay. AC can help review these before ordering.
Solid tumor — newly diagnosed, treatment selection, or disease progression
Liquid biopsy — when tissue is unavailable or repeat sampling is needed
Hematologic malignancy — AML, ALL, MDS/MPN, lymphoma, or multiple myeloma
Homologous recombination deficiency (HRD) — for PARP inhibitor eligibility
MSI/TMB — for immunotherapy candidacy assessment
RNA fusion analysis — where DNA profiling alone may miss fusions
Featured tests
Oncology tests available through AC
GC Genome
ALL Panel
Molecular profiling panel for acute lymphoblastic leukemia.
Specimen: EDTA whole blood / bone marrow
TAT: 12–14 days
GC Genome
AML Panel
Molecular profiling panel for acute myeloid leukemia and related clinical questions.
Specimen: EDTA whole blood / bone marrow
TAT: 12–14 days
GC Genome
Lymphoma Panel
A 60-gene panel for molecular characterization of lymphoid malignancies.
Specimen: EDTA whole blood / bone marrow
TAT: 12–14 days
GC Genome
MDS / MPN Panel
Molecular profiling for myelodysplastic and myeloproliferative neoplasms.
Specimen: EDTA whole blood / bone marrow
TAT: 12–14 days
GC Genome
Multiple Myeloma Panel
Molecular testing panel for plasma-cell neoplasms.
Specimen: EDTA whole blood / bone marrow
TAT: 12–14 days
GC Genome
Solid Tumor — FFPE / Biopsy (+RNA)
Comprehensive solid tumor profiling including hotspot mutations, full-exon coverage, CNV, RNA fusion analysis, MSI, and TMB.
Specimen: FFPE tissue
TAT: 17–21 days
Oncology testing
Start with the clinical question
Share the tumor type, available specimen, and clinical decision point. AC can help identify the appropriate assay and pathway before ordering.
Suite 403, 133 Madina Munawara St, Amman, Jordan
+962 791 707 606 info@advancedconsensus.comMessage us on WhatsAppFor website inquiries, avoid patient names, national IDs, medical record numbers, or reports. Secure document exchange should happen through approved clinical channels.